Otitis Media News and Research

RSS

Acute otitis media (AOM) is a common childhood disease with important ramifications to the overall health of infants and young children. The peak incidence of AOM occurs at 6 to 18 months of age, but it can also occur in older children. Complications of AOM include persistent middle ear effusion, chronic otitis media, transient hearing loss, or speech delays.

Inflammatory marker targeted in ear infection

Systemic injection of an antibody against granulocyte/macrophage colony-stimulating factor inhibits middle-ear inflammation induced by lipopolysaccharide in mice, study findings show.

3 Dec 2012

Allergic rhinitis common in otitis media patients

Allergic rhinitis is a common comorbidity in children with otitis media with effusion, suggest study findings.

2 Nov 2012

Bacterial pathogen ‘acutely’ involved in otitis media

Alloiococcus otitidis can be a dominant bacterial pathogen among indigenous Australian children with acute otitis media with perforation, although its main role appears to be that of a secondary pathogen, preliminary study findings suggest.

10 Oct 2012

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Pfizer Inc. today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age.

5 Oct 2012

Live bacteria in more than 90% of middle ear effusions

Live bacteria are present in more than 90% of middle ear effusions, research shows.

20 Aug 2012

Short course motivates tympanometry use in middle ear problems

The use of tympanometry by general practitioners in the assessment of children with middle ear problems varies considerably, with some clinicians not using it at all, say Danish researchers.

16 Aug 2012

Boric acid treatment equals best practice for otitis media

Study findings show that a single application of boric acid powder followed by external auditory canal irrigation is as effective as topical ciprofloxacin eardrops for treating active chronic otitis media.

6 Aug 2012

Merck welcomes launch of ROTATEQ in Rwanda of Africa’s rotavirus vaccination program

Merck, known as MSD outside the United States and Canada, welcomes today's launch in Rwanda of Africa's first national rotavirus vaccination program with ROTATEQ (rotavirus vaccine, live, oral, pentavalent), Merck's vaccine for the prevention of rotavirus disease.

25 May 2012

ASPO to hold pediatric otolaryngology meeting from April 18 - April 22

The American Society of Pediatric Otolaryngology (ASPO) will hold its annual meeting, April 18 - April 22, during the 2012 Combined Otolaryngology Spring Meetings (COSM) - a joint meeting of eight otolaryngological societies in San Diego, CA. The meeting will feature dozens of scientific presentations highlighting research in progress in the field of otolaryngology-head and neck surgery.

10 Apr 2012

Pfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study endpoints

Pfizer Inc. announced today that data from a Phase 3 study of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years.

12 Mar 2012

Pfizer responds to CDC’S ACIP discussion related to use of Prevnar 13 in adults over 50

Pfizer Inc. issued the following statement in response to today's discussion by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) regarding the use of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine)in adults 50 years of age and older.

23 Feb 2012

FDA approves Prevnar 13 pneumococcal conjugate vaccine for adults 50 and older

Prevnar 13, a pneumococcal 13-valent conjugate vaccine, was approved today by the U.S. Food and Drug Administration for people ages 50 years and older to prevent pneumonia and invasive disease caused by the bacterium, Streptococcus pneumoniae.

31 Dec 2011

Pfizer enters Prevenar 13 supply agreement to protect children from pneumococcal disease

Pfizer Inc. today announced it has entered into a second supply agreement which will broaden and extend the duration of the Company's commitment to help protect millions of infants and young children in the developing world from pneumococcal disease - the leading cause of vaccine-preventable death in young children.

17 Dec 2011

Xylitol can prevent inner ear infections in healthy children

There is "fair evidence" to support the use of xylitol, a natural sweetener used in gums and mints, to prevent inner ear infections in healthy children, a new evidence review finds.

11 Nov 2011

Pfizer's Prevnar 13: Additional data from adult clinical studies presented at 49th IDSA

Pfizer Inc. announced today that additional data from several clinical studies of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine) conducted in adults 50 years and older will be presented during the 49th Annual Meeting of the Infectious Diseases Society of America, which is being held Oct. 20-23, 2011, in Boston, Mass.

22 Oct 2011

Positive new data from Otonomy's OTO-104 Phase 1b study on Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that researchers presented positive new data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease.

29 Sep 2011

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

The 2011 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 11-14, 2011, in San Francisco, CA.

29 Aug 2011

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

Pfizer Inc today announced that the U.S. Food and Drug Administration (FDA) has issued a 90-day extension to the action date for the Company's supplemental Biologics License Application (sBLA) for use of Prevnar 13, in adults aged 50 and older.

30 Jul 2011

Final Atlantis space trip may open new era of research into infectious diseases

On July 8, at approximately 11:26 a.m. EDT, the space shuttle Atlantis will streak skyward from the Kennedy Space Center's launch pad 39A, for one last mission. While the STS-135 flight marks the end of the space shuttle's glory days, its final trip may open a new era of research into infectious diseases, thanks to space bound experiments conducted by Dr's. Cheryl Nickerson, and Roy Curtiss III, along with their colleagues at Arizona State University's Biodesign Institute.

7 Jul 2011

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

A powerful new class of therapeutics, known as recombinant attenuated Salmonella vaccines (RASV), holds great potential in the fight against fatal diseases including hepatitis B, tuberculosis, cholera, typhoid fever, AIDS and pneumonia.

30 Jun 2011